openPR Logo
Press release

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is expected to drive growth of the HIV-associated lipodystrophy treatment market

10-20-2021 09:24 AM CET | Health & Medicine

Press release from: Coherent Market Insights

HIV-Associated Lipodystrophy Treatment Market

HIV-Associated Lipodystrophy Treatment Market

HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of lipodystrophy in people infected with HIV varies between 10% and 80%.

Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1269

Increasing prevalence of HIV is expected to drive growth of the HIV-associated lipodystrophy treatment market

According to an article published in Journal of AIDS & Clinical Research in 2014, prevalence of lipodystrophy in patients suffering from HIV varies significantly and was estimated between 32.4% and 88.6%. According to World Health Organization (WHO) in 2017, more than 35 million people are suffering from HIV worldwide and an estimated 1.0 million people died from HIV in 2016. Increasing prevalence of HIV is expected to drive growth of the HIV-associated lipodystrophy market as most (32.4-88.6%) of the people suffering from HIV also suffer from HIV-associated lipodystrophy.

Approval of novel drugs in key regions such as North America is expected to drive the growth of HIV-Associated Lipodystrophy Market. For instance, in 2014, Theratechnologies Inc. received approval from Health Canada for its EGRIFTA. It is a growth hormone-releasing factor (GRF) for the treatment of HIV-associated lipodystrophy. EGRIFTA had also received the U.S. Food and Drug Administration (FDA) approval in 2010. Such approval of new drugs in the key region is expected to drive growth of the HIV-associated lipodystrophy treatment market.

Global HIV-Associated Lipodystrophy Treatment Market Taxonomy

The global HIV-associated lipodystrophy treatment market is segmented on the basis of lipodystrophy type, therapeutic class, and distribution channel.

On the basis of lipodystrophy type, the global HIV-associated lipodystrophy treatment market is segmented into:

Lipoatrophy
Lipoaccumulation
On the basis of therapeutic class, the global HIV-associated lipodystrophy treatment market is segmented into:

Anabolism modulators
Growth hormones
Anabolic steroids
Insulin resistance modulators
Metformins
Thiazolidinediones
Others
Mitochondrial antioxidants (l-carnitine)
Other miscellaneous metabolic agents
On the basis of the distribution channel, the global HIV-associated lipodystrophy treatment market is segmented into:

Hospital pharmacies
Retail pharmacies
Online pharmacies

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is expected to drive growth of the HIV-associated lipodystrophy treatment market here

News-ID: 2434169 • Views: 259

More Releases from Coherent Market Insights

Water Based Colloidal Graphite Market 2023 Growth, Industry Analysis, Size and S …
The CMI's latest study report sheds light on changing dynamics of each of the segments and subsegments of the "Water Based Colloidal Graphite Market" and examines the investment in the market from 2022-2030. The research report contains all of the relevant facts. It provides market insight by providing accurate data to its clients, allowing them to make critical decisions. It provides an overview of the Water Based Colloidal Graphite market,
Pediatric Interventional Cardiology Market to Reflect Robust Expansion at CAGR o …
The global pediatric interventional cardiology market was valued at US$ 2,019.1 Mn in 2022 and is forecast to reach a value of US$ 3,166.7 Mn by 2030 at a CAGR of 6.6% between 2023 and 2030. The latest research report released by Coherent Market Insights on "Pediatric Interventional Cardiology Market" analysis on business strategy taken up by emerging industry players, geographical scope, market segments, product landscape and value structure. It also
Preventive Vaccines Market to Witness Massive Growth CAGR of 9.4% till 2030 | Sa …
The global preventive vaccines market was valued at US$ 42,660.2 Mn in 2022 and is forecast to reach a value of US$ 80,215.0 Mn by 2030 at a CAGR of 9.4% between 2023 and 2030. The latest research report released by Coherent Market Insights on "Preventive Vaccines Market" analysis on business strategy taken up by emerging industry players, geographical scope, market segments, product landscape and value structure. It also assists in
Sustained Release Coating Market See Incredible Growth 2023-2030 | Evonik, BASF …
The global "Sustained Release Coating Market" report aims to provide a detailed analysis of the factors that influence the global business adoption and segmentation outlook. The detailed information and overview of the global Sustained Release Coating market report highlight the latest development trends across different regions. This report provides key market players with business insights and growth opportunities. The Sustained Release Coating market research is an intelligence report that contains

All 5 Releases


More Releases for HIV

Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral
Approaches to HIV Eradication
The various approaches to HIV eradication all address a problem, and that problem is the HIV reservoir. HIV reservoirs have been called the last hiding place for HIV within the body. The final step toward finding a cure against HIV lies in dealing with HIV reservoirs. Toulon, France, August 30, 2011 - What can be done about HIV eradication? The advancements in scientific technology and medical treatments have made significant progress